- Home
- HSTM vs OPT Comparison
HSTM vs OPT Comparison
Compare HSTM & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- OPT
- Stock Information
- Founded
- HSTM 1990
- OPT 1984
- Country
- HSTM United States
- OPT Australia
- Employees
- HSTM N/A
- OPT N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSTM Technology
- OPT Health Care
- Exchange
- HSTM Nasdaq
- OPT Nasdaq
- Market Cap
- HSTM 979.1M
- OPT 767.9M
- IPO Year
- HSTM 2000
- OPT 2020
- Fundamental
- Price
- HSTM $32.19
- OPT $3.16
- Analyst Decision
- HSTM Hold
- OPT Strong Buy
- Analyst Count
- HSTM 2
- OPT 1
- Target Price
- HSTM $29.00
- OPT $12.00
- AVG Volume (30 Days)
- HSTM 143.1K
- OPT 30.7K
- Earning Date
- HSTM 10-21-2024
- OPT 08-30-2024
- Dividend Yield
- HSTM 0.35%
- OPT N/A
- EPS Growth
- HSTM 52.12
- OPT N/A
- EPS
- HSTM 0.65
- OPT N/A
- Revenue
- HSTM $287,992,000.00
- OPT $261,859.00
- Revenue This Year
- HSTM $6.35
- OPT N/A
- Revenue Next Year
- HSTM $5.23
- OPT $46,864.64
- P/E Ratio
- HSTM $49.59
- OPT N/A
- Revenue Growth
- HSTM 3.96
- OPT N/A
- 52 Week Low
- HSTM $23.92
- OPT $1.79
- 52 Week High
- HSTM $32.93
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- HSTM 61.46
- OPT 27.72
- Support Level
- HSTM $31.21
- OPT $3.22
- Resistance Level
- HSTM $32.27
- OPT $3.37
- Average True Range (ATR)
- HSTM 0.73
- OPT 0.20
- MACD
- HSTM -0.01
- OPT -0.10
- Stochastic Oscillator
- HSTM 79.73
- OPT 5.78
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.